151 related articles for article (PubMed ID: 36796636)
1. Protein Aggregates in Inhaled Biologics: Challenges and Considerations.
Ibrahim M; Wallace I; Ghazvini S; Manetz S; Cordoba-Rodriguez R; Patel SM
J Pharm Sci; 2023 May; 112(5):1341-1344. PubMed ID: 36796636
[TBL] [Abstract][Full Text] [Related]
2. Dry powder pharmaceutical biologics for inhalation therapy.
Chang RYK; Chow MYT; Khanal D; Chen D; Chan HK
Adv Drug Deliv Rev; 2021 May; 172():64-79. PubMed ID: 33705876
[TBL] [Abstract][Full Text] [Related]
3. Inhalable microparticle platform based on a novel shell-forming lipid excipient and its feasibility for respirable delivery of biologics.
Wang H; Connaughton P; Lachacz K; Carrigy N; Ordoubadi M; Lechuga-Ballesteros D; Vehring R
Eur J Pharm Biopharm; 2022 Aug; 177():308-322. PubMed ID: 35905804
[TBL] [Abstract][Full Text] [Related]
4. Advanced therapeutic inhalation aerosols of a Nrf2 activator and RhoA/Rho kinase (ROCK) inhibitor for targeted pulmonary drug delivery in pulmonary hypertension: design, characterization, aerosolization,
Acosta MF; Muralidharan P; Grijalva CL; Abrahamson MD; Hayes D; Fineman JR; Black SM; Mansour HM
Ther Adv Respir Dis; 2021; 15():1753466621998245. PubMed ID: 33719747
[TBL] [Abstract][Full Text] [Related]
5. Spray Freeze Drying of Biologics: A Review and Applications for Inhalation Delivery.
Farinha S; Sá JV; Lino PR; Galésio M; Pires J; Rodrigues MÂ; Henriques J
Pharm Res; 2023 May; 40(5):1115-1140. PubMed ID: 36456666
[TBL] [Abstract][Full Text] [Related]
6. Comparison of l-Carnitine and l-Carnitine HCL salt for targeted lung treatment of pulmonary hypertension (PH) as inhalation aerosols: Design, comprehensive characterization, in vitro 2D/3D cell cultures, and in vivo MCT-Rat model of PH.
Acosta MF; Muralidhran P; Abrahamson MD; Grijalva CL; Carver M; Tang H; Klinger C; Fineman JR; Black SM; Mansour HM
Pulm Pharmacol Ther; 2020 Dec; 65():101998. PubMed ID: 33556627
[TBL] [Abstract][Full Text] [Related]
7. Inhalable Nanoparticle-based Dry Powder Formulations for Respiratory Diseases: Challenges and Strategies for Translational Research.
Chan HW; Chow S; Zhang X; Zhao Y; Tong HHY; Chow SF
AAPS PharmSciTech; 2023 Apr; 24(4):98. PubMed ID: 37016029
[TBL] [Abstract][Full Text] [Related]
8. Synergistic antibacterial effect of inhaled aztreonam and tobramycin fixed dose combination to combat multidrug-resistant Gram-negative bacteria.
Wang J; Kutter JP; Mu H; Moodley A; Yang M
Int J Pharm; 2020 Nov; 590():119877. PubMed ID: 32927003
[TBL] [Abstract][Full Text] [Related]
9. Focusing on powder processing in dry powder inhalation product development, manufacturing and performance.
Stegemann S; Faulhammer E; Pinto JT; Paudel A
Int J Pharm; 2022 Feb; 614():121445. PubMed ID: 34998921
[TBL] [Abstract][Full Text] [Related]
10. Spray drying siRNA-lipid nanoparticles for dry powder pulmonary delivery.
Zimmermann CM; Baldassi D; Chan K; Adams NBP; Neumann A; Porras-Gonzalez DL; Wei X; Kneidinger N; Stoleriu MG; Burgstaller G; Witzigmann D; Luciani P; Merkel OM
J Control Release; 2022 Nov; 351():137-150. PubMed ID: 36126785
[TBL] [Abstract][Full Text] [Related]
11. Formulation of High-Performance Dry Powder Aerosols for Pulmonary Protein Delivery.
Wilson EM; Luft JC; DeSimone JM
Pharm Res; 2018 Aug; 35(10):195. PubMed ID: 30141117
[TBL] [Abstract][Full Text] [Related]
12. Spray-Dried and Spray-Freeze-Dried Powder Formulations of an Anti-Interleukin-4Rα Antibody for Pulmonary Delivery.
Pan HW; Seow HC; Lo JCK; Guo J; Zhu L; Leung SWS; Zhang C; Lam JKW
Pharm Res; 2022 Sep; 39(9):2291-2304. PubMed ID: 35879500
[TBL] [Abstract][Full Text] [Related]
13. Inhaled dry powder formulations for treating tuberculosis.
Das S; Tucker I; Stewart P
Curr Drug Deliv; 2015; 12(1):26-39. PubMed ID: 25030114
[TBL] [Abstract][Full Text] [Related]
14. Solid state of inhalable high dose powders.
Adhikari BR; Gordon KC; Das SC
Adv Drug Deliv Rev; 2022 Oct; 189():114468. PubMed ID: 35917868
[TBL] [Abstract][Full Text] [Related]
15. Design, characterization, and aerosol dispersion performance modeling of advanced spray-dried microparticulate/nanoparticulate mannitol powders for targeted pulmonary delivery as dry powder inhalers.
Li X; Vogt FG; Hayes D; Mansour HM
J Aerosol Med Pulm Drug Deliv; 2014 Apr; 27(2):81-93. PubMed ID: 24502451
[TBL] [Abstract][Full Text] [Related]
16. Design, physicochemical characterization, and optimization of organic solution advanced spray-dried inhalable dipalmitoylphosphatidylcholine (DPPC) and dipalmitoylphosphatidylethanolamine poly(ethylene glycol) (DPPE-PEG) microparticles and nanoparticles for targeted respiratory nanomedicine delivery as dry powder inhalation aerosols.
Meenach SA; Vogt FG; Anderson KW; Hilt JZ; McGarry RC; Mansour HM
Int J Nanomedicine; 2013; 8():275-93. PubMed ID: 23355776
[TBL] [Abstract][Full Text] [Related]
17. Development of inhalable hyaluronan/mannitol composite dry powders for flucytosine repositioning in local therapy of lung infections.
Costabile G; d'Angelo I; d'Emmanuele di Villa Bianca R; Mitidieri E; Pompili B; Del Porto P; Leoni L; Visca P; Miro A; Quaglia F; Imperi F; Sorrentino R; Ungaro F
J Control Release; 2016 Sep; 238():80-91. PubMed ID: 27449745
[TBL] [Abstract][Full Text] [Related]
18. Spray-Dried Inhalable Powder Formulations of Therapeutic Proteins and Peptides.
Eedara BB; Alabsi W; Encinas-Basurto D; Polt R; Mansour HM
AAPS PharmSciTech; 2021 Jun; 22(5):185. PubMed ID: 34143327
[TBL] [Abstract][Full Text] [Related]
19. Characterization and aerosol dispersion performance of advanced spray-dried chemotherapeutic PEGylated phospholipid particles for dry powder inhalation delivery in lung cancer.
Meenach SA; Anderson KW; Zach Hilt J; McGarry RC; Mansour HM
Eur J Pharm Sci; 2013 Jul; 49(4):699-711. PubMed ID: 23707466
[TBL] [Abstract][Full Text] [Related]
20. Inhaled fixed-dose combination powders for the treatment of respiratory infections.
Brunaugh AD; Sharma S; Smyth H
Expert Opin Drug Deliv; 2021 Aug; 18(8):1101-1115. PubMed ID: 33632051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
